Keywords: biogen, idec, initiates, ph, iii, trial, adentri

Biogen Idec initiates Ph III trial of Adentri

Article | 01 September 2008

Print This

US drugmaker Biogen Idec has initiated a Phase III trial of intravenous Adentri (BG9928), an adenosine A1 receptor antagonist, for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in